Cowen analyst Joshua Jennings initiated MediWound with an Outperform rating as he believes the company has two best-in-class debridement agents in Nexobrid and EscharEx. He believes the products should prove their value over the coming years, which will establish it as a truly novel tissue technology company. Jennings has a $9 price target on MediWound shares.

MediWound announced that recent clinical data from EscharEx Phase II studies will be presented throughout May 2024 at the largest, most prestigious annual meetings in the field of chronic wound care: the European Wound Management Association, the Wound Healing Society, and the Symposium on Advanced Wound Care. The oral presentations on EscharEx will include: Comparative data of EscharEx vs. SANTYL that demonstrate EscharEx's superiority over the current leading enzymatic debridement agent; New analyses from the ChronEx phase II study, showing high correlation between wound bed preparation and wound healing; These data indicate that EscharEx could substantially improve wound care for patients with debilitating chronic wounds, providing significant benefits over the current standard of care. Additionally, the findings support the design and endpoints of the upcoming Phase III study, which is expected to begin in the second half of 2024. "We are delighted to present the results of additional analyses from EscharEx Phase II studies in chronic hard-to-heal wounds, including the positive comparative data with SANTYL(R), the current dominant standard of care for enzymatic debridement," said Dr. Robert J. Snyder, Chief Medical Officer of MediWound. "With its robust efficacy, favorable safety profile, and multimodal mechanistic effects demonstrated in these Phase II studies, we believe that EscharEx can significantly advance wound care and has the potential to become a major player in the global wound care market."